Lakefront Biotherapeutics N.V.
LKFT
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B
$28.81
▲ +0.91%
P/E
112.95
Mkt Cap
$1.9B
52-Wk Range
$25.68–$37.78
52-Week Range
$25.68 - $37.78
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 8.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Profitability at risk
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
+4.7% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LKFT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 10, 2026
Reported EPS of -$0.24 vs -$0.82 consensus (+71.3% surprise). Revenue of $14.0M vs $6.1M expected (+128.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+71.3%
Revenue trend · last 1Q
—
Q1 26
$7.5M
Margins · last 1Q
Profit
223.6%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How LKFT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.